Johnson & Johnson (JNJ) Interest & Investment Income (2009 - 2026)
Johnson & Johnson (JNJ) posted Interest & Investment Income of $219.0 million for Q2 2026, down 4.37% sequentially from $229.0 million in Q1 2026, and down 15.77% YoY from $260.0 million in Q2 2025.
Johnson & Johnson (JNJ) Interest & Investment Income (2009 - 2026) Analysis & Trends
Johnson & Johnson has reported Interest & Investment Income for 18 years, with the latest figure at $219.0 million in Q2 2026.
- Quarterly Interest & Investment Income fell 15.77% year-over-year to $219.0 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $912.0 million (down 21.72% YoY) and the FY2025 annual result came in at $1.1 billion, down 20.72% from the prior year.
- Interest & Investment Income declined to $219.0 million in Q2 2026 per JNJ's latest filing, from $229.0 million in the prior quarter.
- Over five years, Interest & Investment Income peaked at $450.0 million in Q1 2023 and troughed at $22.0 million in Q2 2022.
- A 5-year average of $265.7 million and a median of $270.5 million in 2024 frame the typical range for Interest & Investment Income.
- The sharpest annual moves came in 2022 and 2025: Interest & Investment Income jumped 1053.85% in 2022, then tumbled 34.18% in 2025.
- Over 5 years, Interest & Investment Income stood at $150.0 million in 2022, then surged by 142.0% to $363.0 million in 2023, then fell by 22.59% to $281.0 million in 2024, then declined by 15.66% to $237.0 million in 2025, then declined by 7.59% to $219.0 million in 2026.
- According to Business Quant data, Interest & Investment Income over the past three periods registered $219.0 million, $229.0 million, and $237.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.88 Bn | 625.12 Bn | 17.26 Bn | 219.00 Mn |
| 2 | AbbVie | 463.46 Bn | 456.89 Bn | 12.70 Bn | -679.00 Mn |
| 3 | Merck | 367.92 Bn | 360.78 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 297.71 Bn | 290.02 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 255.55 Bn | 250.65 Bn | 12.86 Bn | 80.00 Mn |
| 6 | Amgen | 234.52 Bn | 220.53 Bn | 7.24 Bn | - |
| 7 | Gilead Sciences | 178.22 Bn | 175.04 Bn | 6.22 Bn | - |
| 8 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | - |
| 9 | Gsk | 105.32 Bn | 101.15 Bn | 8.24 Bn | 77.82 Mn |
| 10 | Sanofi | 54.20 Bn | 46.82 Bn | 10.79 Bn | 89.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 28, 2026 | 219.00 Mn |
| Mar 29, 2026 | 229.00 Mn |
| Dec 28, 2025 | 237.00 Mn |
| Sep 28, 2025 | 227.00 Mn |
| Jun 29, 2025 | 260.00 Mn |
| Mar 30, 2025 | 332.00 Mn |
| Dec 29, 2024 | 281.00 Mn |
| Sep 29, 2024 | 292.00 Mn |
| Jun 30, 2024 | 395.00 Mn |
| Mar 31, 2024 | 364.00 Mn |
| Dec 31, 2023 | 363.00 Mn |
| Oct 1, 2023 | 374.00 Mn |
| Jul 2, 2023 | 326.00 Mn |
| Apr 2, 2023 | 198.00 Mn |
| Jan 1, 2023 | 450.00 Mn |
| Oct 2, 2022 | 150.00 Mn |
| Jul 3, 2022 | 64.00 Mn |
| Apr 3, 2022 | 22.00 Mn |
| Oct 3, 2021 | 13.00 Mn |
| Jul 4, 2021 | 12.00 Mn |